2-Star Stocks Poised to Plunge: Optimer Pharmaceuticals?

Before you go, we thought you'd like these...
Before you go close icon

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, drug developer Optimer Pharmaceuticals (NAS: OPTR) has received a distressing two-star ranking.

With that in mind, let's take a closer look at Optimer's business and see what CAPS investors are saying about the stock right now.

Optimerfacts

Headquarters (founded)San Diego (1998)
Market Cap$641.4 million
IndustryPharmaceuticals
Trailing-12-Month Revenue$145.0 million
ManagementCEO Pedro Lichtinger (since 2010)
Chief Scientific Officer Sherwood Gorbach (since 2011)
Return on Capital (average, past 3 years)(50.8%)
Cash/Debt$110.6 million / $0
CompetitorsBayer
Pfizer
Sanofi

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 24% of the 144 members who have rated Optimer believe the stock will underperform the S&P 500 going forward.

Just last week, one of those bears, All-Star zzlangerhans, cautioned Fools about getting excited over Optimer's antibiotic Dificid:

This was one of my former favorite stocks. ... However, Dificid is not off to an awesome start, with flat revenues around [$10 million] in the first two quarters of the US launch. The stock is still getting some of the benefit of the doubt, having risen from recent lows around [$10 per share] seen towards the end of 2011. However, that upward float renders the stock susceptible for a major gap downward if Q1 2012 revenues disappoint. Ominously, I haven't heard any buzz about Dificid or seen any patients who have been treated with it. Optimer has also terminated development of their other advanced pipeline compound, Pruvel, leaving Dificid to bear sole responsibility for the company's future.

If you want to retire rich, you need to protect your portfolio from any undue risk. Luckily, we've compiled a special free report for investors called "Discover the Next Rule-Breaking Multibagger," which uncovers another small-cap growth play with big potential. The report is 100% free, but it won't be around forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the newTrackPoisedToCAPS account.

At the time this article was published Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners